117 related articles for article (PubMed ID: 36053771)
21. Transition of average drug-to-antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography-tandem mass spectrometry.
Habara H; Okamoto H; Nagai Y; Oitate M; Takakusa H; Watanabe N
Biopharm Drug Dispos; 2023 Oct; 44(5):380-384. PubMed ID: 37534716
[TBL] [Abstract][Full Text] [Related]
22. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
Vasalou C; Proia TA; Kazlauskas L; Przybyla A; Sung M; Mamidi S; Maratea K; Griffin M; Sargeant R; Urosevic J; Rosenbaum AI; Yuan J; Aluri KC; Ramsden D; Hariparsad N; Jones RDO; Mettetal JT
CPT Pharmacometrics Syst Pharmacol; 2024 Mar; ():. PubMed ID: 38532525
[TBL] [Abstract][Full Text] [Related]
23. Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action.
Nagai Y; Oitate M; Shibayama T; Takakusa H; Watanabe N
Drug Metab Pharmacokinet; 2024 Jan; 56():101001. PubMed ID: 38643548
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
Sathe AG; Singh I; Singh P; Diderichsen PM; Wang X; Chang P; Taqui A; Phan S; Girish S; Othman AA
Clin Pharmacokinet; 2024 May; 63(5):669-681. PubMed ID: 38578394
[TBL] [Abstract][Full Text] [Related]
25. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F
J Clin Oncol; 2024 Apr; ():JCO2301909. PubMed ID: 38652877
[TBL] [Abstract][Full Text] [Related]
26. Model-informed dose selection for an investigational human epidermal growth factor receptor 2 antibody-drug conjugate FS-1502 in patients with human epidermal growth factor receptor 2-expressing advanced malignant solid tumours.
Sun Y; Li C; Wang X; Zheng Y; Wu Z; Hui AM; Diao L
Br J Clin Pharmacol; 2024 Apr; 90(4):1115-1129. PubMed ID: 37926561
[TBL] [Abstract][Full Text] [Related]
27. Use of Real-World Evidence in a Virtual Bridging Analysis for a Human Epidermal Growth Factor Receptor 2-Targeted Antibody-Drug Conjugate in Gastric Cancer.
Lu Z; Wada R; Salas M; Singh J; Kawaguchi Y; Belli AJ; Abutarif M; Garimella T
J Clin Pharmacol; 2023 Nov; 63(11):1244-1255. PubMed ID: 37377133
[TBL] [Abstract][Full Text] [Related]
28. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract][Full Text] [Related]
29. The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.
Trinder A; Ding K; Zhang J
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38231075
[TBL] [Abstract][Full Text] [Related]
30. Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Lu Y; Liang S; Hong Y; Tajima N; Patel K; Li H; Wada DR; Greenberg J; Petrich A; Zebger-Gong H; Shuster D; Vaddady P
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):23-28. PubMed ID: 37915242
[TBL] [Abstract][Full Text] [Related]
31. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis.
Gadaleta-Caldarola G; Lanotte L; Infusino S; Gadaleta-Caldarola A; Schipilliti FM; Citrigno C; Petrarota C; Cusmai A; Rizzo A
Cancer Treat Res Commun; 2023; 37():100775. PubMed ID: 37956525
[TBL] [Abstract][Full Text] [Related]
32. Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC.
Chen Q; Jia G; Zhang X; Ma W
Front Immunol; 2024; 15():1376045. PubMed ID: 38357544
[TBL] [Abstract][Full Text] [Related]
33. Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Apr; ():. PubMed ID: 38648979
[TBL] [Abstract][Full Text] [Related]
34. Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report.
de Weger VA; Schutte T; Konings IRHM; Menke-van der Houven van Oordt CW
J Breast Cancer; 2023 Oct; 26(5):519-523. PubMed ID: 37926069
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Agnostic Treatment Heading to the Clinic?
Cancer Discov; 2023 Dec; 13(12):OF10. PubMed ID: 37888905
[TBL] [Abstract][Full Text] [Related]
36. Concurrent trastuzumab deruxtecan-induced interstitial lung disease and COVID-19 in the treatment of advanced breast cancer.
Yasuda N; Ikeo S; Sokai A; Sakai Y; Hayashi Y; Kitano S; Itoi N; Lee T; Iwata T; Nishimura T
Oxf Med Case Reports; 2023 Dec; 2023(12):omad135. PubMed ID: 38145267
[TBL] [Abstract][Full Text] [Related]
37. Two cases of trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer.
Gocho K; Sato K; Iizuka N; Sunada K; Nishiya S; Hamanaka N
Respirol Case Rep; 2022 Apr; 10(4):e0928. PubMed ID: 35280717
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
Tu YP; Hanze E; Zhu F; Lagraauw HM; Sloss CM; Method M; Esteves B; Westin EH; Berkenblit A
Br J Clin Pharmacol; 2024 Feb; 90(2):568-581. PubMed ID: 37872122
[TBL] [Abstract][Full Text] [Related]
39. Development of an ELISA with acidification treatment for an antibody conjugate incorporating Exatecans.
Zhang Y; Yun X; Ouyang L; Zhang X; Gong L; Qin Q
Anal Biochem; 2024 Jul; 690():115530. PubMed ID: 38570023
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
